100 Or More Amino Acid Residues In The Peptide Chain Patents (Class 514/21.2)
-
Patent number: 9688666Abstract: The present disclosure relates to novel crystalline salt forms of lamivudine, methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of viruses such as Human Immunodeficiency Virus (HIV) infection.Type: GrantFiled: February 6, 2014Date of Patent: June 27, 2017Assignee: TOBIRA THERAPEUTICS, INC.Inventors: Sean Mark Dalziel, Mark Michael Menning
-
Patent number: 9587007Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.Type: GrantFiled: October 27, 2014Date of Patent: March 7, 2017Assignee: AbbVie Biotherapeutics Inc.Inventors: Yoshiko Akamatsu, Veronica Juan, Robert B. Dubridge
-
Patent number: 9572863Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits IL-4 and/or IL-13 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.Type: GrantFiled: December 12, 2012Date of Patent: February 21, 2017Assignee: Pieris Pharmaceuticals GmbHInventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
-
Patent number: 9528122Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:3-5, or the nucleotide sequence set forth in SEQ ID NO:2, as well as variants and fragments thereof.Type: GrantFiled: July 27, 2012Date of Patent: December 27, 2016Assignee: Athenix Corp.Inventors: Kimberly S Sampson, Duane A Lehtinen
-
Patent number: 9518127Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.Type: GrantFiled: July 20, 2012Date of Patent: December 13, 2016Assignees: CSL Behring GmbH, CSL Ltd.Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
-
Patent number: 9512215Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.Type: GrantFiled: December 15, 2014Date of Patent: December 6, 2016Assignee: ARES TRADING S.A.Inventors: Fabrizio Samaritani, Alessandra Del Rio, Rita Agostinetto
-
Patent number: 9500641Abstract: Compositions and methods for altering cell activity and function by expressing a light-activated ion pump polypeptide in a cell and contacting the cell with light that activates the expressed light-activated ion pump polypeptide. In some aspects of the invention, a light-activated ion pump polypeptide is a modified haloarcula halorhodopsin polypeptide, for example, a modified Halo 57 polypeptide.Type: GrantFiled: January 20, 2015Date of Patent: November 22, 2016Assignee: Massachusetts Institute of TechnologyInventors: Amy Chuong, Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Xue Han
-
Patent number: 9441231Abstract: The present invention provides regulatory polynucleotide molecules isolated from plant proline rich protein genes and linked to a viral enhancer molecule. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the regulatory polynucleotide sequences, and methods for preparing and using the same.Type: GrantFiled: December 5, 2008Date of Patent: September 13, 2016Assignee: Monsanto Technology LLCInventors: Stanislaw Flasinski, Shirley Xiaoli Guo, Wei Wu
-
Patent number: 9328154Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.Type: GrantFiled: April 16, 2014Date of Patent: May 3, 2016Assignee: DUKE UNIVERSITYInventor: Ashutosh Chilkoti
-
Patent number: 9314510Abstract: The present invention relates to human laminin ?2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin ?2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKC? and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.Type: GrantFiled: March 12, 2012Date of Patent: April 19, 2016Assignee: SNU R&DB FoundationInventor: Byung-Moo Min
-
Patent number: 9302002Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: October 18, 2012Date of Patent: April 5, 2016Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Brian Murphy
-
Patent number: 9175045Abstract: Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins; and methods of identifying and making such improved polypeptides.Type: GrantFiled: August 2, 2013Date of Patent: November 3, 2015Assignee: Aileron Therapeutics, Inc.Inventors: Huw M. Nash, David Allen Annis, Rosanna Kapeller-Libermann, Tomi K. Sawyer, Noriyuki Kawahata
-
Patent number: 9138463Abstract: The present invention relates to compositions for delivering carbon monoxide (CO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of MalPEG surface modified hemoglobin to deliver CO to cells.Type: GrantFiled: October 19, 2011Date of Patent: September 22, 2015Inventors: Robert M. Winslow, Nancy Jo Winslow, Kim Vandegriff, Ashok Malavalli
-
Patent number: 9121021Abstract: Methods for the treatment of a disorder characterized by excessive proliferation and/or lipid content of sebocytes are disclosed. In one embodiment of the invention, the method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a small molecule inhibitor targeted to galectin-12 or a nucleic acid-based inhibitor targeted to galectin-12 and a pharmaceutically acceptable carrier, wherein said inhibitor is a non-naturally occurring molecule and administration of said inhibitor produces a decrease in the proliferation and/or lipid content of the sebocytes. Methods for decreasing sebaceous gland size, inhibiting sebocyte proliferation, and/or inhibiting sebocyte lipid content are also disclosed.Type: GrantFiled: November 6, 2014Date of Patent: September 1, 2015Assignee: ACADEMIA SINICAInventors: Fu-Tong Liu, Wei-Chen Hsieh, Ri-Yao Yang
-
Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
Patent number: 9066966Abstract: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).Type: GrantFiled: February 1, 2013Date of Patent: June 30, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), CNRS (Centre National de la Recherche Scientifique), Universite de Strasbourg, Cornell University, Universite Paris-Sud XI, Assistance Publique-Hopitaux de Paris (APHP)Inventors: Helene Monique Puccio, Patrick Aubourg, Ronald G. Crystal, Pierre Bougneres -
Patent number: 9045542Abstract: The present invention includes compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of allergy, and asthma.Type: GrantFiled: August 28, 2012Date of Patent: June 2, 2015Assignee: Baylor Research InstituteInventors: SangKon Oh, Jacques F. Banchereau, Gerard Zurawski, Hideki Ueno, Ling Ni
-
Publication number: 20150139999Abstract: Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.Type: ApplicationFiled: June 5, 2014Publication date: May 21, 2015Inventors: Sergei V. Kotenko, Geoffrey L. Smith
-
Patent number: 9034817Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.Type: GrantFiled: December 17, 2013Date of Patent: May 19, 2015Assignee: CONARIS RESEARCH INSTITUTE AGInventors: Georg H. Wätzig, Dirk Seegert
-
Publication number: 20150133530Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: ApplicationFiled: May 15, 2013Publication date: May 14, 2015Applicant: University of Florida Research Foundation, Inc.Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-Mckenna
-
Publication number: 20150132286Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.Type: ApplicationFiled: September 18, 2014Publication date: May 14, 2015Inventors: Bruno DOMON, Ian MCCAFFREY, Vaibhav NARAYAN, Scott PATTERSON
-
Patent number: 9029328Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.Type: GrantFiled: March 24, 2011Date of Patent: May 12, 2015Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of TechnologyInventors: Steven M. Jay, Linda G. Griffith, Richard T. Lee
-
Patent number: 9029315Abstract: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In addition, the subject invention can be used in the prevention and/or treatment of tumor or cancer.Type: GrantFiled: November 11, 2011Date of Patent: May 12, 2015Assignee: The University of Hong KongInventors: Zhiwei Chen, Jingying Zhou
-
Patent number: 9029320Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.Type: GrantFiled: August 26, 2013Date of Patent: May 12, 2015Assignee: Red Mountain Med Spa, LLCInventors: Mark Bentz, Suzanne Bentz, Riccardo Roscetti, M. Socorro Parra Arenas
-
Patent number: 9029331Abstract: The invention relates to methods of preparing and purifying conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are purified using various chromatography methods.Type: GrantFiled: January 10, 2006Date of Patent: May 12, 2015Assignee: Novo Nordisk A/SInventors: Shawn DeFrees, Henrik Clausen, David A. Zopf, Caryn Bowe, Susann Taudte, Michael Felo, Walter S. Willett
-
Publication number: 20150126452Abstract: The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc. Disclosed are furthermore novel protein or peptide structures, nucleic acids encoding same and cloning and expression vectors suitable for carrying out the inventive method for assembling multimeric proteins or peptides.Type: ApplicationFiled: May 28, 2013Publication date: May 7, 2015Inventors: Stefan Schiller, Matthias Huber
-
Publication number: 20150126459Abstract: The invention relates to the treatment of a hypersensitivity immune response caused by a non-profilin allergen of a profilin-containing plant material (e.g. grass or tree pollen) by bystander suppression with a plant profilin (e.g. Phl p 12, Bet v 2, or Ole e 2) or a variant thereof. Also the invention features a particular variant of Phl p 12 with two of its cysteine residues replaced with another amino acid to increase its pharmaceutical properties.Type: ApplicationFiled: April 16, 2013Publication date: May 7, 2015Inventors: Kaare Lund, Jens Brimnes, Helene Henmar, Hans-Henrik Ipsen, Lise Lund Mærkedahl, Gitte Nordskov Hansen, Rafael Ignacio Monsalve Clemente
-
Patent number: 9023798Abstract: The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from cystinosis.Type: GrantFiled: July 23, 2010Date of Patent: May 5, 2015Assignee: The Regents of the University of MichiganInventors: Jess Thoene, Jeffrey Innis
-
Patent number: 9023799Abstract: A method to treat the chronic stage of heart injury after ischemia or reperfusion by administering Midkine to a subject in need of such treatment is described.Type: GrantFiled: December 6, 2005Date of Patent: May 5, 2015Assignee: Cellmid LimitedInventors: Mitsuru Horiba, Itsuo Kodama, Takashi Muramatsu, Kenji Kadomatsu
-
Publication number: 20150119333Abstract: The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods.Type: ApplicationFiled: September 18, 2013Publication date: April 30, 2015Applicant: La Jolla Institute for Allergy and ImmunologyInventors: Klaus LEY, Christian GLEISSNER
-
Publication number: 20150119339Abstract: A method of care is described that includes administering an effective amount of ?-hydroxy-?-methylbutyrate (HMB) to an adult or elderly patient to decrease the risk of an adverse health event during or subsequent to hospitalization of the patient.Type: ApplicationFiled: June 10, 2013Publication date: April 30, 2015Applicant: ABBOTT LABORATORIESInventors: Menghua Luo, Jeffrey L. Nelson, Anne C. Voss, Owen J. Kelly, Geraldine E. Baggs, Min Tian, Jamie Partridge
-
Publication number: 20150110778Abstract: Disclosed herein are compositions and methods for the treatment and/or protection of airway cells and/or tissue from damage due to injury to the lungs or complications of underlying respiratory, cardiovascular or infectious diseases, or any combination thereof.Type: ApplicationFiled: September 6, 2012Publication date: April 23, 2015Applicant: Rutgers, the State University of New JerseryInventors: Jianjie Ma, Noah Weisleder
-
Publication number: 20150111822Abstract: There are provided compositions and methods for modulating stem cell division, in particular, division symmetry. It has been demonstrated that Wnt7a polypeptide fragments promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro, ex vivo, and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.Type: ApplicationFiled: September 14, 2012Publication date: April 23, 2015Inventors: Michael A. Rudnicki, Conrad Florian Bentzinger, Radoslav Zinoviev
-
Patent number: 9011853Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.Type: GrantFiled: August 31, 2010Date of Patent: April 21, 2015Assignee: Amplimmune, Inc.Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
-
Patent number: 9012401Abstract: The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.Type: GrantFiled: March 3, 2006Date of Patent: April 21, 2015Assignees: Biopharm Gesellschaft zur biotechnolgischen Entwicklung von Pharmaka mbH, Charite-Universitatsmedizin Berlin, Freie Universitat BerlinInventors: Stefan Mundlos, Petra Knaus, Jens Pohl, Michael Kruse, Frank Plöger
-
Patent number: 9012408Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.Type: GrantFiled: March 27, 2013Date of Patent: April 21, 2015Assignee: Bristol-Myers Squibb CompanyInventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
-
Patent number: 9012409Abstract: B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.Type: GrantFiled: March 28, 2013Date of Patent: April 21, 2015Assignee: Mayo Foundation for Medical Education and ResearchInventor: Lieping Chen
-
Publication number: 20150105333Abstract: Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-?B activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-?B activity without a second delayed increase in NF-?B activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated Massilia bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). Also provided are methods of culturing the Massilia bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by Massilia bacteria, optionally with a priming agent.Type: ApplicationFiled: October 17, 2014Publication date: April 16, 2015Inventors: Olaf Kutsch, Michael Niederweis, Frank Wolschendorf, Alexandra Duverger, Frederic Wagner
-
Patent number: 9005616Abstract: Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.Type: GrantFiled: August 31, 2010Date of Patent: April 14, 2015Assignee: Amplimmune, Inc.Inventors: Solomon Langermann, Linda Liu
-
Publication number: 20150098908Abstract: The invention relates to the field of medicine. In particular, it relates to recombinant cationic polypeptides and their use as biolubricant. Provided is a biolubricant substance comprising the amino acid sequence[(GKGVP)9]n, wherein n is ?5.Type: ApplicationFiled: October 4, 2013Publication date: April 9, 2015Applicants: ACADEMISCH ZIEKENHUIS GRONINGEN, RIJKSUNIVERSITEIT GRONINGENInventors: PRASHANT KUMAR SHARMA, ANDREAS HERRMANN, ANKE KOLBE, DEEPAK HALENAHALLY VEEREGOWDA
-
Publication number: 20150099695Abstract: Compositions and methods for treatment of obesity and/or Type II diabetes and related metabolic disorders are provided wherein the methods and treatments comprise an effective amount of an isolated and/or purified C1q/TNF-related Protein-9 (CTRP9) or a functional portion thereof, and a pharmaceutically acceptable carrier. Methods of screening for molecules which elevate levels of CTRP9 in vivo are also provided. The present inventors provide the first in vivo evidence linking CTRP9 to regulation of fat metabolism in liver and skeletal muscle via AMPK signaling pathway, and highlight its protective metabolic function in the context of HFD-mediated metabolic insults.Type: ApplicationFiled: May 28, 2013Publication date: April 9, 2015Inventors: Guang William Wong, Jonathan M. Peterson
-
Publication number: 20150099708Abstract: The invention provides novel Wnt polypeptides that have improved production characteristics, solubility, systemic delivery, and tissue uptake, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting muscle hypertrophy and growth.Type: ApplicationFiled: September 14, 2012Publication date: April 9, 2015Inventors: Tom Tong Lee, Michael J. Fitch, Kevin Lai, Peter Flynn, Monica Bennett
-
Publication number: 20150093334Abstract: A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an organism, to a specific tissue, to specific cells, or to an environmental medium, by sequestering the one or more than one substance within a vault-like particle. A method of delivering one or more than one substance or a sensor to an organism, to a specific tissue, to specific cells, or to an environmental medium. According to another embodiment of the present invention, there is provided a method of making vault-like particles, and making vault-like particles comprising one or more than one substance, or one or more than one sensor.Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Leonard H. Rome, Valerie A. Kickhoefer, Sujna Raval-Fernandes, Phoebe Stewart
-
Publication number: 20150093340Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.Type: ApplicationFiled: September 30, 2014Publication date: April 2, 2015Inventors: Gregory H. Altman, Rebecca L. Horan, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
-
Publication number: 20150094266Abstract: Compositions include synergistic combinations of xyloglucans and vegetable or animal proteins that are useful in the treatment of intestinal disorders or of disorders originating from the intestinal system and transferred to other systems, such as the genitourinary system. The compositions include xyloglucans or an extract containing xyloglucans, and one or more animal or vegetable proteins. Methods for the treatment or prevention of intestinal disorders are provided, including prevention of diarrhoea.Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Applicant: Novintethical Pharma, SAInventors: Marco Di Fulvio, Miguel Angel Alonso, Michele Giuseppe Di Schiena
-
Patent number: 8993524Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immune suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.Type: GrantFiled: March 4, 2011Date of Patent: March 31, 2015Assignee: The Johns Hopkins UniversityInventors: Atul Bedi, Rajani Ravi
-
Publication number: 20150087602Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in whey protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in whey protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in whey protein.Type: ApplicationFiled: March 15, 2013Publication date: March 26, 2015Inventors: Geoffrey von Maltzahn, Michael J. Hamill, Rajeev Chillakuru, John F. Kramarczyk, David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver
-
COMPOSITIONS ASSOCIATED WITH AND METHODS OF MANAGING NEUTROPHIL MOVEMENT USING SERUM AMYLOID P (SAP)
Publication number: 20150087576Abstract: The disclosure also relates to a method of reducing the number of neutrophils in a body region by administering a Serum Amyloid P (SAP) composition in an amount and for a time sufficient to suppress neutrophil movement into the body region. In particular, it relates to a method of reducing the number of neutrophils in a body region suffering from an acute injury or from a chronic or long-term disease. Further, the disclosure relates to a method of increasing the number of neutrophils in a body region by administering an anti-SAP antibody or material able to bind SAP. The disclosure further relates to compositions usable with these methods.Type: ApplicationFiled: December 13, 2012Publication date: March 26, 2015Inventors: Richard Gomer, Anu S. Maharjan, David J. Roife -
Patent number: 8987205Abstract: Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.Type: GrantFiled: March 8, 2013Date of Patent: March 24, 2015Assignee: Wyeth LLCInventors: Carl Ralph Flannery, Christopher John Corcoran, Bethany Annis Freeman, Lisa A. Collins-Racie
-
Patent number: 8987208Abstract: The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism.Type: GrantFiled: May 24, 2013Date of Patent: March 24, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Edwin R. Chapman, Min Dong
-
Patent number: 8986951Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: GrantFiled: June 8, 2011Date of Patent: March 24, 2015Assignee: Pieris AGInventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian